Adipokine (adiponectin-rs1501299) Gene Variant and Patient Characteristics in Relation to Metabolic-associated Fatty Liver Disease

IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY
Amal A. Mohamed , Soha Hassanin , Ahmed A. Mohamed , Dalia Zaafar , Rasha Mohamed , Mohamed B. Hassan , Al-Shaymaa A. Hassanin , Eman Alsayed Abouahmad , Mohamed A. Sakr , Soha M. Abd el salam , Reem A.M. Abdelghafour , Nashwa M. Muharram , Marwa K. Darwish , Saadia faried , Karmia Nasraldin , Wael Hafez
{"title":"Adipokine (adiponectin-rs1501299) Gene Variant and Patient Characteristics in Relation to Metabolic-associated Fatty Liver Disease","authors":"Amal A. Mohamed ,&nbsp;Soha Hassanin ,&nbsp;Ahmed A. Mohamed ,&nbsp;Dalia Zaafar ,&nbsp;Rasha Mohamed ,&nbsp;Mohamed B. Hassan ,&nbsp;Al-Shaymaa A. Hassanin ,&nbsp;Eman Alsayed Abouahmad ,&nbsp;Mohamed A. Sakr ,&nbsp;Soha M. Abd el salam ,&nbsp;Reem A.M. Abdelghafour ,&nbsp;Nashwa M. Muharram ,&nbsp;Marwa K. Darwish ,&nbsp;Saadia faried ,&nbsp;Karmia Nasraldin ,&nbsp;Wael Hafez","doi":"10.1016/j.jceh.2024.101409","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Several genetic and metabolic variables, most notably the variation in the adipokine gene rs1501298, have been linked to metabolic-associated fatty liver disease etiopathogenesis (MAFLD). Liver biopsy, the gold standard for diagnosing MAFLD, is an invasive procedure; therefore, alternative diagnostic methods are required. Consequently, the integration of these metabolic variables with some of the patients’ characteristics may facilitate the development of noninvasive diagnostic methods that aid in the early detection of MAFLD, identification of at-risk individuals and planning of management strategies.</p></div><div><h3>Methods</h3><p>This study included 224 Egyptians (107 healthy individuals and 117 MAFLD patients). Age, sex, BMI, clinical and laboratory characteristics, and rs1501299 adipokine gene polymorphisms were examined. The rs1501299 variant, insulin resistance, hypertension, obesity, blood pressure, lipid profile, hemoglobin A1C level, and hepatic fibrosis predictors were evaluated for MAFLD risk. The feasibility and effectiveness of developing non-invasive MAFLD diagnostic models will be investigated.</p></div><div><h3>Results</h3><p>The +276G/T (rs1501299) polymorphism (GG vs GT/TT) was linked with MAFLD (OR: 0.43, CI: 0.26–0.69, <em>P</em> = 0.002). The GG variants had lower MAFLD rates than those of the GT and TT variants. In addition to altered lipid profiles, patients with MAFLD showed increased gamma-glutamyl transferase levels (GGT: 56 IU/L vs. 36 IU/L). Genetic diversity also affects the accuracy of hepatic fibrosis and steatosis prediction. Hepatic fibrosis and steatosis predictors had receiver operating characteristic (ROC) AUCs of 0.529%, 0.846%, and 0.700–0.825%, respectively. We examined a diagnostic model based on these variables and demonstrated its effectiveness.</p></div><div><h3>Conclusion</h3><p>The Adipokine variant rs1501299 increased the risk of MAFLD. Identifying and genotyping this variation and other metabolic variables allow for a noninvasive diagnostic model for early MAFLD diagnosis and identification of those at risk. This study illuminates the prevention and management of MAFLD. Further research with more participants is needed to verify these models and to prove their MAFLD diagnostic efficacy.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 5","pages":"Article 101409"},"PeriodicalIF":3.3000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0973688324000665","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Several genetic and metabolic variables, most notably the variation in the adipokine gene rs1501298, have been linked to metabolic-associated fatty liver disease etiopathogenesis (MAFLD). Liver biopsy, the gold standard for diagnosing MAFLD, is an invasive procedure; therefore, alternative diagnostic methods are required. Consequently, the integration of these metabolic variables with some of the patients’ characteristics may facilitate the development of noninvasive diagnostic methods that aid in the early detection of MAFLD, identification of at-risk individuals and planning of management strategies.

Methods

This study included 224 Egyptians (107 healthy individuals and 117 MAFLD patients). Age, sex, BMI, clinical and laboratory characteristics, and rs1501299 adipokine gene polymorphisms were examined. The rs1501299 variant, insulin resistance, hypertension, obesity, blood pressure, lipid profile, hemoglobin A1C level, and hepatic fibrosis predictors were evaluated for MAFLD risk. The feasibility and effectiveness of developing non-invasive MAFLD diagnostic models will be investigated.

Results

The +276G/T (rs1501299) polymorphism (GG vs GT/TT) was linked with MAFLD (OR: 0.43, CI: 0.26–0.69, P = 0.002). The GG variants had lower MAFLD rates than those of the GT and TT variants. In addition to altered lipid profiles, patients with MAFLD showed increased gamma-glutamyl transferase levels (GGT: 56 IU/L vs. 36 IU/L). Genetic diversity also affects the accuracy of hepatic fibrosis and steatosis prediction. Hepatic fibrosis and steatosis predictors had receiver operating characteristic (ROC) AUCs of 0.529%, 0.846%, and 0.700–0.825%, respectively. We examined a diagnostic model based on these variables and demonstrated its effectiveness.

Conclusion

The Adipokine variant rs1501299 increased the risk of MAFLD. Identifying and genotyping this variation and other metabolic variables allow for a noninvasive diagnostic model for early MAFLD diagnosis and identification of those at risk. This study illuminates the prevention and management of MAFLD. Further research with more participants is needed to verify these models and to prove their MAFLD diagnostic efficacy.

脂肪因子(脂肪连接蛋白-rs1501299)基因变异和患者特征与代谢相关性脂肪肝的关系
背景几种遗传和代谢变量,尤其是脂肪因子基因 rs1501298 的变异,与代谢相关性脂肪肝(MAFLD)的发病机制有关。肝活检是诊断 MAFLD 的金标准,但它是一种侵入性操作,因此需要其他诊断方法。因此,将这些代谢变量与患者的一些特征相结合,可能有助于开发无创诊断方法,帮助早期发现 MAFLD、识别高危人群并规划管理策略。对年龄、性别、体重指数、临床和实验室特征以及 rs1501299 脂肪因子基因多态性进行了研究。评估了 rs1501299 变异、胰岛素抵抗、高血压、肥胖、血压、血脂概况、血红蛋白 A1C 水平和肝纤维化对 MAFLD 风险的预测作用。结果+276G/T(rs1501299)多态性(GG vs GT/TT)与 MAFLD 有关(OR:0.43,CI:0.26-0.69,P = 0.002)。GG变异体的MAFLD发生率低于GT和TT变异体。除了血脂谱改变外,MAFLD 患者的γ-谷氨酰转移酶水平也升高(GGT:56 IU/L vs. 36 IU/L)。遗传多样性也会影响肝纤维化和脂肪变性预测的准确性。肝纤维化和脂肪变性预测因子的接受者操作特征(ROC)AUC 分别为 0.529%、0.846% 和 0.700-0.825%。我们研究了基于这些变量的诊断模型,并证明了其有效性。对这一变异及其他代谢变量进行识别和基因分型,可建立一个无创诊断模型,用于早期诊断 MAFLD 和识别高危人群。这项研究阐明了如何预防和管理 MAFLD。要验证这些模型并证明其对 MAFLD 诊断的有效性,还需要对更多参与者进行进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical and Experimental Hepatology
Journal of Clinical and Experimental Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
4.90
自引率
16.70%
发文量
537
审稿时长
64 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信